Press Releases

Aurora BioPharma Chosen for Innovation Challenge at RESI Boston 2017

CAMBRIDGE, MA, September 13, 2017-- Aurora BioPharma is one of 40 companies selected from a pool of over 100 applicants to compete in the Life Science Nation's RESI Innovation Challenge on September 26, 2017 in Boston. The event will take at the Boston Marriott Copley Place on September 26, 2017. The conference attracts attendees from the U.S. and 25 other countries. They include qualified investors or strategic partners, scientists, and C-Level Executives from emerging companies in the biopharmaceutical and biotechnology sectors.

About the RESI Innovation Challenge:Thirty North American companies, selected by Life Science Nation's scientific and commercial review team will present directly to investors and potential partners in a poster/exhibition-style format during the RESI conference. Companies will also be competing with each other in a virtual investment contest on the basis of demonstrated innovation and commercial viability.

About RESI: The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that establishes a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on a diverse breadth of early stage investors including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

About Aurora BioPharma

Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients, showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma patients showing safety, tumor-killing and a Complete Response -- cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.

​For more information, please visit or follow us:


Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For media inquiries, please contact:

Candace Cobos

Aurora BioPharma, Inc.

Tel: (617) 674-7718 - Fax: (617) 674-7701

SOURCE Aurora BioPharma, Inc.